Clinical Trial Update: Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update investigating the combination of Anlotinib with an Anti-PD-1 antibody (AK105) for advanced pancreatic cancer across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AK105 (Anti-PD-1 Antibody) (anti-PD-1 antibody)
• Anlotinib (anlotinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Anlotinib, Anti-PD-1 Antibody | Phase 1, Phase 2 | Status: UNKNOWN